LEXICON PHARMACEUTICALS INC (LXRX) 2.02 -0.11 (-5.16%)
2.02 -0.11 (-5.16%)
US5288723027 - Common Stock - After market: 2.02 0 (0%)
Fundamental Rating
We assign a fundamental rating of 2 out of 10 to LXRX. LXRX was compared to 631 industry peers in the Biotechnology industry. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative. LXRX is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
LXRX's Return On Assets of -50.64% is in line with the rest of the industry. The industry average Return On Assets is -44.51%.
The profitability ratios for LXRX are negative, so there is not much use analyzing them.
LXRX has a Profit Margin of -77648.80%. This is below the industry average of -464.10%. 98% of the industry peers outperform LXRX.
The Piotroski-F score of LXRX is 3.00. This is a low score and indicates issues in the health and profitability of LXRX.
VS Industry
ROA (-50.64%) VS Industry: 42% outperformed.
-950.38
52.28
Profit Margin (-77648.8%) VS Industry: 2% outperformed.
-1,173,705.71
34,743.00
Valuation
Valuation Rating
When comparing the current price to the book value of LXRX, we can conclude it is valued correctly. It is trading at 2.65 times its book value.
The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
When comparing the price book ratio of LXRX to the average industry price book ratio of 1.67, LXRX is valued more expensive than its industry peers.
VS Industry
Price/Book (2.65) VS Industry: 32% outperformed.
130.23
0.10
Growth
Growth Rating
LXRX is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 14.04% yearly.
Based on estimates for the next 5 years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 1349.40% on average per year.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The earnings per share for LXRX have decreased strongly by -29.17% in the last year.
Looking at the last year, LXRX shows a very negative growth in Revenue. The Revenue has decreased by -72.65% in the last year.
LXRX shows a very negative growth in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -67.27% yearly.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -29.17% | -1.16% | -2.66% | 25.27% | 14.04% |
| Revenue | -67.27% | -83.23% | -72.65% | -49.32% | 712.15% | 681.72% | 1349.4% |
Health
Health Rating
LXRX has a Current Ratio of 7.54. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 7.54 indicates that LXRX has no problem at all paying its short term obligations.
LXRX has a Current Ratio comparable to the industry average, which is at 6.18.
LXRX has a Quick Ratio comparable to the industry average, which is at 6.05.
Compared to an average industry Debt to Equity Ratio of 0.00, LXRX is more dependent on financing than its industry peers.
LXRX has an Altman-Z score of -7.22. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.76, LXRX is in worse financial health than its industry peers.
LXRX has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of LXRX.
VS Industry
Debt/Equity (0.17) VS Industry: 21% outperformed.
15.37
0.00
Quick Ratio (7.54) VS Industry: 60% outperformed.
0.02
84.53
Current Ratio (7.54) VS Industry: 59% outperformed.
0.02
85.09
Altman-Z (-7.22) VS Industry: 22% outperformed.
-135.10
484.91
Dividend
Dividend Rating
No dividends for LXRX!.
LEXICON PHARMACEUTICALS INC2.02
NASDAQ:LXRX (11/28/2022, 7:04:14 PM)-0.11 (-5.16%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-09 2022-11-09/amc | Earnings (Next) | 02-27 2023-02-27 |
| Ins Owners | 1% | Inst Owners | 78.84% |
| Market Cap | 381.23M | Analysts | 82.22 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 3049.81 | P/B | 2.65 |
| EV/EBITDA | -1.81 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -29.17% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 18.75% |
| EPS Next Y | -1.16% | EPS Next 2Y | -2.66% |
| EPS Next 3Y | 25.27% | EPS Next 5Y | 14.04% |
| Revenue growth 1Y | -72.65% | Revenue growth 3Y | -83.23% |
| Revenue growth 5Y | -67.27% | Revenue growth Q2Q | 69.57% |
| Revenue Next Year | -49.32% | Revenue Next 2Y | 712.15% |
| Revenue Next 3Y | 681.72% | Revenue Next 5Y | 1349.4% |
| Current Ratio | 7.54 | Quick Ratio | 7.54 |
| Altman-Z | -7.22 | F-Score | 3 |
| Debt/Equity | 0.17 | WACC | 9.31% |
| ROIC/WACC | N/A | ||
| ROA | -50.64% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | -77648.8% | OM | -76649.6% |
| Asset Turnover | 0 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA